Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00401687 · ClinicalTrials.gov registry record · Phase 4
DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function
A Phase 4 study of Ventricular Ejection Fraction, sponsored by Lantheus Medical Imaging.
- Completed
- Registry status
- Phase 4
- Development phase
- 131
- Enrollment target
- 10
- Study locations
NCT00401687: Completed Phase 4 study of Ventricular Ejection Fraction, sponsored by Lantheus Medical Imaging.
NCT00401687 is a Phase 4 study of Ventricular Ejection Fraction that has completed, run by Lantheus Medical Imaging. The registered enrollment target is 131 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00401687, a Phase 4 study of Ventricular Ejection Fraction, has completed, sponsored by Lantheus Medical Imaging.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 131 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this clinical research study is to demonstrate the ability of Definity® enhanced versus unenhanced cardiac ultrasound to improve the accuracy and reproducibility of left ventricular ejection fraction (EF) when compared to magnetic resonance imaging (MRI).
Conditions Studied
Interventions
- DRUG Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
Study Locations (10)
Arizona
- University of Arizona - Tucson
Illinois
- University of Chicago Medical Center - Chicago
Maryland
- Washington Hospital Center - Washington DC
Missouri
- Saint Lukes Mid America Heart Institute - Kansas City
Nebraska
- University of Nebraska Medical Center - Omaha
North Carolina
- Duke University Medical Center - Durham
Ohio
- Cleveland Clinic Foundation - Cleveland
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2006-07 |
| Est. Completion | 2008-04 |
| Phase | Phase 4 |
What the finished NCT00401687 record still lists
NCT00401687 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Ventricular Ejection Fraction appearing as the primary indexed condition, and to 1 intervention - of which Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension is the first listed.
NCT00401687 lists 10 locations in 10 states (Arizona, Illinois, Maryland).
Frequently Asked Questions
What is clinical trial NCT00401687 about?
NCT00401687 is a clinical study titled "DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function". The purpose of this clinical research study is to demonstrate the ability of Definity® enhanced versus unenhanced cardiac ultrasound to improve the accuracy and reproducibility of left ventricular ejection fraction (EF) when compared to magnetic resonance imaging (MRI).
What is the current status of trial NCT00401687?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 131 participants. The study started on 2006-07. Estimated completion is 2008-04.
What conditions does trial NCT00401687 study?
This clinical trial studies the following conditions: Ventricular Ejection Fraction.
What interventions are being tested in trial NCT00401687?
The interventions under investigation include: Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension (DRUG).
Who is sponsoring clinical trial NCT00401687?
This trial is sponsored by Lantheus Medical Imaging, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00401687 being conducted?
This trial has 10 study locations across Arizona, Illinois, Maryland, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ventricular Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00401687's enrollment target sits among peer trials
131 619th of 2000 higher than 1,379 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03051464 · 131 participants · Phase 2
No Surgery Trial / Two Dose-escalation Strategies
- NCT04301843 · 131 participants · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- NCT04748549 · 131 participants · NA
Intraoperative VR for Older Patients Undergoing TKA
- NCT05951179 · 131 participants · Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia